lenalidomide + hepatitis B vaccine

This research regimen consists of the immunomodulatory drug lenalidomide administered as an adjuvant in combination with the Hepatitis B vaccine. Developed and studied by the Boston VA Research Institute, Inc., the combination is designed to enhance the immune response to vaccination in patients with plasma cell dyscrasias, such as multiple myeloma, monoclonal gammopathy of unknown significance (MGUS), and Waldenström's Macroglobulinemia. These patients typically exhibit a reduced response to standard vaccinations due to underlying immune dysfunction. Lenalidomide, a small molecule derivative of thalidomide, acts as an immunomodulatory imide drug (IMiD) that binds to cereblon, part of the E3 ubiquitin ligase complex, leading to the degradation of specific transcription factors and the subsequent stimulation of T-cell and natural killer (NK) cell activity. In this context, it serves as a molecular adjuvant to boost the production of antibodies against the hepatitis B surface antigen provided by the vaccine.

Brand names

Revlimid

Other names

lenalidomide + HBV vaccineR-Boston VA Research Institute, Inc.-Hepatitis B